Henlius Biotech FDA Accepts aBLA for Avastin Biosimilar HLX04
Henlius Biotech’s Avastin Biosimilar Bid Signals Intensifying Competition in Oncology
The FDA’s acceptance of Shanghai Henlius Biotech’s application for HLX04, a biosimilar to Genentech’s Avastin (bevacizumab), on January 13, 2026, isn’t just another regulatory milestone. It’s a clear indicator of the escalating competition within the oncology biosimilars market. This move, alongside pending applications from Samsung Bioepis and Centus/Fujifilm Kyowa Kirin, underscores a pivotal shift in how cancer treatments are accessed and priced.
The Rise of Biosimilars: Lowering Costs, Expanding Access
Biosimilars, essentially generic versions of biologic drugs, are designed to be highly similar to their reference products. Their introduction is crucial for driving down healthcare costs. Avastin, used to treat various cancers including colorectal, lung, and kidney cancer, is a significant expense for patients and healthcare systems. The success of existing Avastin biosimilars – six are already approved in the U.S. – demonstrates the potential for substantial savings. Currently, biosimilars account for a staggering 92% of the bevacizumab market share, with Amgen/Allergan’s Mvasi holding the largest slice at 54%, according to Samsung Bioepis’s Q4 2025 Biosimilar Market Report.
Did you know? The first Avastin biosimilar, Mvasi, was approved in 2017, marking a turning point in the U.S. Biosimilars landscape.
Henlius Biotech: A Growing Force in the Biosimilars Arena
Henlius Biotech isn’t a newcomer to the biosimilars game. The company already boasts a portfolio of approved biosimilars in the U.S., including Hercessi (a Herceptin biosimilar), Bildyos/Bilprevda (Prolia/Xgeva biosimilars), and Poherdy (an interchangeable Perjeta biosimilar). This established track record lends credibility to their Avastin biosimilar application and suggests a continued commitment to expanding affordable treatment options. Their success highlights a growing trend of Asian biopharmaceutical companies making significant inroads into the global biosimilars market.
What’s Driving the Biosimilar Boom in Oncology?
Several factors are fueling the growth of oncology biosimilars. Firstly, the high cost of innovative cancer therapies creates a strong demand for more affordable alternatives. Secondly, patent expirations on blockbuster drugs like Avastin open the door for biosimilar development. Finally, increasing regulatory clarity and streamlined approval pathways, like the FDA’s abbreviated Biologics licence Application (aBLA) process, are accelerating the time it takes to bring biosimilars to market.
Pro Tip: Understanding the nuances of the aBLA process is crucial for biopharmaceutical companies looking to enter the biosimilars market. It requires demonstrating high similarity to the reference product, but avoids the need for extensive clinical trials.
Future Trends: Interchangeability and Market Consolidation
Looking ahead, several key trends will shape the oncology biosimilars landscape. Interchangeability – the ability for a pharmacist to substitute a biosimilar for the reference product without physician intervention – will be a major battleground. While Henlius’s Poherdy is an interchangeable Perjeta biosimilar, achieving interchangeability for other products requires additional clinical data. This distinction is critical, as interchangeable biosimilars are expected to gain faster market adoption.
Another trend is likely to be market consolidation. As the number of biosimilar competitors increases, smaller players may struggle to compete. We could see more mergers and acquisitions as companies seek to gain scale and expand their portfolios. The focus will shift towards developing biosimilars for increasingly complex biologics, including antibody-drug conjugates (ADCs) and cell therapies.
The Absence of Patent Disputes: A Positive Sign
Currently, the lack of pending patent disputes related to Avastin biosimilars is a positive sign for market entry and competition. Patent litigation can significantly delay biosimilar launches and increase development costs. However, this doesn’t guarantee a dispute-free future, as patent challenges can emerge at any stage of the process.
Frequently Asked Questions (FAQ)
Q: What is a biosimilar?
A: A biosimilar is a highly similar, but not identical, copy of an already approved biologic drug. They offer a more affordable treatment option.
Q: Are biosimilars as safe and effective as the original biologic?
A: Yes. Biosimilars undergo rigorous testing to demonstrate they are highly similar to the reference product in terms of safety, efficacy, and quality.
Q: What is interchangeability?
A: Interchangeability means a biosimilar can be substituted for the reference product by a pharmacist without the need for physician approval, similar to how generic drugs are substituted.
Q: Where can I find more information about biosimilars?
A: The FDA website is a great resource for information on biosimilars. You can also find valuable insights from organizations like Biosimilar News.
We encourage you to explore our other articles on biosimilar development and oncology market trends to stay informed about this rapidly evolving field. Share your thoughts and questions in the comments below!